Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

The BARDA vaccine MCM IDIQ seeks contractors capable of developing, manufacturing, and delivering influenza vaccine countermeasures—including antigens, adjuvants, formulation, fill‑finish, storage, and related clinical and non‑clinical services—for pandemic preparedness and response. Eligible firms must hold an FDA‑licensed influenza vaccine or have a BLA filed, be SAM‑registered, and meet extensive CGMP, security, data‑rights, and reporting requirements. The contract will be a 5‑year base period with one optional 5‑year extension, and will be structured as a multiple‑award IDIQ with firm‑fixed‑price, unit‑price, and cost‑reimbursement task orders. • Scope covers the full product life‑cycle: CVV generation, seed‑lot production, bulk manufacturing, formulation/fill‑finish, labeling, storage, shipping, analytical testing, non‑clinical and clinical studies, and disposal. • Mandatory deliverables include detailed security, project‑management, regulatory, manufacturing, and continuity plans, plus monthly/annual technical progress reports and weekly dose‑tracking during a public‑health emergency. • Award will be based on technical capability (Factor A), past performance (Factor B), and price (Factor C); up to four contracts may be awarded; no ceiling disclosed but multi‑year, multi‑hundred‑million‑dollar potential.